Yahoo! Finance Search - Finance Home - Yahoo! - Help

Monday, February 27 2017 12:05pm ET - U.S. Markets close in 3 hours and 55 minutes.
Industry Center - Drug Delivery
Industry Center > Drug Delivery > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Drug Delivery News
Latest News
Monday, Feb 27, 2017
·Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod
PR Newswire - 2 hours, 35 minutes ago
·Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod
CNW Group - 2 hours, 35 minutes ago
Friday, Feb 24, 2017
·Valeant's Ugly Earnings History May Repeat Itself
at Barrons.com - Fri Feb 24
·Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage® XR
GlobeNewswire - Fri Feb 24
Thursday, Feb 23, 2017
·Did 50 Salespeople Leave Valeant? Wells Fargo Investigates
at Barrons.com - Thu Feb 23
·Obagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products
PR Newswire - Thu Feb 23
·Obagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products
CNW Group - Thu Feb 23
·NovaDel Pharma Inc. Announces Dissolution of the Company
Business Wire - Wed Feb 22
Wednesday, Feb 22, 2017
·Published Review Shows Delcath Investigational PHP Doubles Overall Survival Over Other Targeted Liver Therapies
GlobeNewswire - Wed Feb 22
·​Tiny Waltham biotech's market cap doubles after $103M Valeant licensing deal
at bizjournals.com - Tue Feb 21
Tuesday, Feb 21, 2017
·Valeant Acquires Eyegate Licensing Rights
at TheStreet.com - Tue Feb 21
·Generex Provides Access Information for Investor Conference Call Scheduled for February 22, 2017
Business Wire - Tue Feb 21
·Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory Board
GlobeNewswire - Tue Feb 21
·Analysis From Two Institutions Shows Strong Tumor Response, Overall Survival Potential of Delcath Investigational PHP Therapy
GlobeNewswire - Tue Feb 21
·EyeGate Pharma surges 15% on news of Valeant licensing agreement
- Tue Feb 21
·EyeGate Pharma surges 15% on news of Valeant licensing agreement
at MarketWatch - Tue Feb 21
·Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients
PR Newswire - Tue Feb 21
·Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients
CNW Group - Tue Feb 21
Friday, Feb 17, 2017
·AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial
at TheStreet.com - Fri Feb 17
Thursday, Feb 16, 2017
·Why This FDA Approval for Valeant Is Not as Good as First Thought
- Thu Feb 16
More Latest News...
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drug Delivery Headlines
More Finance RSS Feeds


Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2017 Morningstar, Inc. All Rights Reserved. Company information © 2017 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2017, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?